Elevance Health, Inc. with ticker code (ELV) have now 19 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $625.00 and $388.00 and has a mean target at $493.39. Given that the stocks previous close was at $400.30 this now indicates there is a potential upside of 23.3%. Also worth taking note is the 50 day moving average now sits at $388.51 and the 200 moving average now moves to $483.61. The total market capitalization for the company now stands at 92.61B. The price for the stock stands currently at: $399.32 USD
The potential market cap would be $114,148,841,633 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.55, revenue per share of $747.41 and a 5.84% return on assets.
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
